Advanced Enzyme Technologies Limited
NSE: ADVENZYMES · Biotechnology
Snapshot
Unlock Advanced Enzyme Technologies Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Advanced Enzyme Technologies Limited is a biotechnology company that researches, develops, manufactures, and markets a wide range of enzymes and probiotics. Its products serve diverse industries including human healthcare, animal nutrition, food processing, and various industrial applications like textiles and biofuels.
Business Model
The company generates revenue through the research, production, and global sale of enzyme-based solutions and probiotics. It operates across multiple sectors, leveraging its expertise in biocatalysis to provide specialised processing aids for both food and non-food industrial applications.
- Founded:1957
Growth Outlook
Growth is driven by the increasing adoption of enzyme-based solutions in food processing and industrial manufacturing to improve efficiency and sustainability. The company continues to expand its international footprint and diversify its product portfolio across healthcare and specialty applications.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory requirements for its healthcare and food-grade enzyme products across different international markets.
- Technological Obsolescence. Rapid advancements in biotechnology require continuous investment in research and development to maintain a competitive edge.
- Foreign Exchange Volatility. As an exporter with global operations, the company is exposed to fluctuations in currency exchange rates that may impact profitability.
- Raw Material Costs. Fluctuations in the cost of raw materials used in the fermentation and production processes can affect operating margins.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Advanced Enzyme Technologies Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹746 Cr
TTM · consolidated
NET PROFIT
₹174 Cr
TTM · consolidated
EPS
₹15.08
TTM · consolidated
RETURN ON EQUITY
11.8%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
14.9%
TTM · consolidated
P/E
21.6x
Q4 FY26 · consolidated
EV/EBITDA
13.5x
Q4 FY26 · consolidated
EBITDA MARGIN
35.4%
TTM · consolidated
NET PROFIT MARGIN
22.3%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0%
Q4 FY26 · consolidated
Peers · Biotechnology
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Advanced Enzyme Technologies LimitedADVENZYMES | 3,024 | 21.56 | 13.46 | 17.1% | 35.4% | 11.8% | 14.9% | -0.9% |
Anthem Biosciences Ltd.ANTHEM | 35,806 | 105.85 | 42.86 | — | 46.6% | 19.5% | 26.8% | — |
As of Q4 FY26
Financials
Advanced Enzyme Technologies Limited
NSE: ADVENZYMES · Biotechnology
Snapshot
Unlock Advanced Enzyme Technologies Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Advanced Enzyme Technologies Limited is a biotechnology company that researches, develops, manufactures, and markets a wide range of enzymes and probiotics. Its products serve diverse industries including human healthcare, animal nutrition, food processing, and various industrial applications like textiles and biofuels.
Business Model
The company generates revenue through the research, production, and global sale of enzyme-based solutions and probiotics. It operates across multiple sectors, leveraging its expertise in biocatalysis to provide specialised processing aids for both food and non-food industrial applications.
- Founded:1957
Growth Outlook
Growth is driven by the increasing adoption of enzyme-based solutions in food processing and industrial manufacturing to improve efficiency and sustainability. The company continues to expand its international footprint and diversify its product portfolio across healthcare and specialty applications.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory requirements for its healthcare and food-grade enzyme products across different international markets.
- Technological Obsolescence. Rapid advancements in biotechnology require continuous investment in research and development to maintain a competitive edge.
- Foreign Exchange Volatility. As an exporter with global operations, the company is exposed to fluctuations in currency exchange rates that may impact profitability.
- Raw Material Costs. Fluctuations in the cost of raw materials used in the fermentation and production processes can affect operating margins.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Advanced Enzyme Technologies Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹746 Cr
TTM · consolidated
NET PROFIT
₹174 Cr
TTM · consolidated
EPS
₹15.08
TTM · consolidated
RETURN ON EQUITY
11.8%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
14.9%
TTM · consolidated
P/E
21.6x
Q4 FY26 · consolidated
EV/EBITDA
13.5x
Q4 FY26 · consolidated
EBITDA MARGIN
35.4%
TTM · consolidated
NET PROFIT MARGIN
22.3%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0%
Q4 FY26 · consolidated
Peers · Biotechnology
As of Q4 FY26